30183-14-3

Usage

General Description

1H-Benzimidazole-2-carbonylchloride(9CI) is a chemical compound with the molecular formula C8H5ClN2O. It is a derivative of benzimidazole and is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. 1H-Benzimidazole-2-carbonylchloride(9CI) is a white to off-white solid with a melting point of around 177-178°C. It is known to react violently with water, alcohols, and amines, and should be handled with caution. 1H-Benzimidazole-2-carbonylchloride(9CI) is primarily used in the pharmaceutical industry for the production of various drugs due to its ability to act as a versatile building block in organic synthesis.

Upstream product

• 2849-93-6 2-benzimidazolecarboxylic acid 

Relevant academic research and scientific papers

Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis

Schistosomiasis is a major neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. In this study, we chemically optimized our previously reported benzhydroxamate-based inhibitors of Schistosoma mansoni histone deacetylase 8 (smHDAC8). Crystallographic analysis provided insights into the inhibition mode of smHDAC8 activity by the highly potent inhibitor 5o. Structure-based optimization of the novel inhibitors was carried out using the available crystal structures as well as docking studies on smHDAC8. The compounds were evaluated in screens for inhibitory activity against schistosome and human HDACs (hHDAC). The in vitro and docking results were used for detailed structure activity relationships. The synthesized compounds were further investigated for their lethality against the schistosome larval stage using a fluorescence-based assay. The most promising inhibitor 5o showed significant dose-dependent killing of the schistosome larvae and markedly impaired egg laying of adult worm pairs maintained in culture.

Structure-based design of novel benzimidazole derivatives as PIN1 inhibitors

Peptidyl-prolyl cis/trans isomerase Pin1 plays a key role in amplifying and translating multiple oncogenic signaling pathways during oncogenesis. The blockade of Pin1 provided a unique way of disrupting multiple oncogenic pathways and inducing apoptosis. Aiming to develop potent Pin1 inhibitors, a series of benzimidazole derivatives were designed and synthesized. Among the derivatives, compounds 6h and 13g showed the most potent Pin1 inhibitory activity with IC50 values of 0.64 and 0.37 μM, respectively. In vitro antiproliferative assay demonstrated that compounds 6d, 6g, 6h, 6n, 6o and 7c exhibited moderate antiproliferative activity against human prostate cancer PC-3 cells. Taken together, these unique benzimidazole derivatives exhibited great potential to be further explored as potent Pin1 inhibitors with improved potency.

Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin

We recently discovered RnpA as a promising new drug discovery target for methicillin-resistant S. aureus (MRSA). RnpA is an essential protein that is thought to perform two required cellular processes. As part of the RNA degrasome Rnpa mediates RNA degradation. In combination with rnpB it forms RNase P haloenzymes which are required for tRNA maturation. A high throughput screen identified RNPA2000 as an inhibitor of both RnpA-associated activities that displayed antibacterial activity against clinically relevant strains of S. aureus, including MRSA. Structure-activity studies aimed at improving potency and replacing the potentially metabotoxic furan moiety led to the identification of a number of more potent analogs. Many of these new analogs possessed overt cellular toxicity that precluded their use as antibiotics but two derivatives, including compound 5o, displayed an impressive synergy with mupirocin, an antibiotic used for decolonizing MSRA whose effectiveness has recently been jeopardized by bacterial resistance. Based on our results, compounds like 5o may ultimately find use in resensitizing mupirocin-resistant bacteria to mupirocin.

Syntheses, Crystal Structures, and Spectral Characterization of Six Novel Benzimidazolyl Substituted Triaryltriazoles

Six new benzimidazolyl substituted triaryltriazoles, 3-(2-pyridyl)-4-(p-R-phenyl)-5-(2-benzimidazolyl)-1,2,4-triazoles (L1: R?=?OCH3; L2: R?=?CH3; L3: R?=?H; L4: R?=?Br; L5: R?=?Cl; L6: R?=?F) were successfully synthesized. Yield of L1–6 is in the range from 61 to 76%. The compounds L1–6 were characterized by UV–vis, FTIR, 1H-NMR, ESI-MS spectra, and elemental analysis. Additionally, the absolute configurations of L1–5 were determined by single crystal X-ray crystallography.

Synthesis, in-vitro microbial and cytotoxic studies of new benzimidazole derivatives

Several new classes of benzimidazole derivatives were synthesized and evaluated for in-vitro antimicrobial and cytotoxic activities. The results showed that all synthesized compounds exhibited moderate antimicrobial activity, and compounds 2, 4, and 13 displayed cytotoxic activity (as LD50) at the concentration 1 × 10-3 M against Artemia salina.